



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 332776536 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 145, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 7, 2003

Signature: 

(Tamara Alcaraz)

PATENT  
Docket No. 033136119



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

the application of:

Richard G. MILLER and  
Brian RABINOVICH

Serial No.: 09/541,033

Filing Date: March 31, 2000

For: COMBINATION THERAPY FOR  
AUTOIMMUNE AND ALLOIMMUNE  
DISEASES

Examiner: J. H. Roark

Group Art Unit: 1644

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

In reviewing its file, Applicants noticed that it did not have a copy of the Form 1449 initialed by the Examiner (Paper No. 5) as acknowledged in her Office Action (Paper

07/10/2003 EAREGAY1 00000126 031952 09541033

01 FC:1806 180.00 DA

No. 9) mailed on May 4, 2001. Applicants would be grateful if the Examiner was able to provide Applicants with a copy of the initialed Form 1449.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - A fee is required. A check in the amount of \_\_ is enclosed.
  - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of \_\_ is enclosed.
  - A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 033136119. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 7, 2003

Respectfully submitted,

By:   
Gerald F. Swiss  
Registration No. 30,113

Morrison & Foerster LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
Telephone: (650) 813-5600  
Facsimile: (650) 494-0792

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)



Docket Number 033136119	Application Number 09/541,033
Inventor(s)	Richard G. MILLER and Brian RABINOVICH
Filing Date March 31, 2000	Group Art Unit 1644
Mailing Date June 7, 2003	Examiner Name J. H. Roark

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Document Date (MM/DD/YYYY)	Document No.	Name	Filing Date If Appropriate
1.	11/06/1990	4,968,483	Müller et al.		

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Publication Date (MM/DD/YYYY)	Document No.	Country	Translation YES NO
2.	02/26/1998	WO 98/07436	WIPO		

## OTHER DOCUMENTS

(including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	3.	Åkerlund, K. et al., (January 1999) "Anti-Inflammatory Effects of a New Tumour Necrosis Factor-Alpha (TNF- $\alpha$ ) Inhibitor (NCI-1493) in Collagen-Induced Arthritis (CIA) in Rats," <i>Clin. &amp; Exp. Immunol.</i> 115(1):32-41.
	4.	Morrow, J. K. (January 15, 1997) "Companies Take Broad Range of Approaches to Develop Rheumatoid Arthritis Therapies," <i>Genetic Engineering News</i> Volume 17, Number 2, pp. 1, 7, 26.
	5.	Pearson, C. M. (1956) "Development of Arthritis, Periarthritis and Periostitis in Rats Given Adjuvants," <i>Proc. Soc. Exp. Biol. Med.</i> 91(1):95-101.
	6.	Ross, S. E. et al., (December 15, 1997) "Suppression of TNF- $\alpha$ Expression, Inhibition of Th1 Activity, and Amelioration of Collagen-Induced Arthritis by Rolipram," <i>J. Immunol.</i> 159(12):6253-6259.
	7.	Terato, K. and Reife, R. A. (May 7, 2002) "A Novel Model of Arthritis Induced With Monoclonal Antibodies to Type II Collagen," <i>Stratagene Internet Website</i> located at < <a href="http://www.stratagene.com/vol11_2/p56-57.htm">http://www.stratagene.com/vol11_2/p56-57.htm</a> > visited on May 7, 2002, 3 pages.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.